These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7747265)

  • 21. FDA board investigates Depo-Provera safety.
    Contracept Technol Update; 1983 Mar; 4(3):25-7. PubMed ID: 12266161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teratogenicity of recently introduced medications in human pregnancy.
    Lo WY; Friedman JM
    Obstet Gynecol; 2002 Sep; 100(3):465-73. PubMed ID: 12220765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethical and legal aspects of teratogenic medications: the case of isotretinoin.
    Moskop JC; Smith ML; De Ville K
    J Clin Ethics; 1997; 8(3):264-78. PubMed ID: 9436085
    [No Abstract]   [Full Text] [Related]  

  • 24. Evolving knowledge of the teratogenicity of medications in human pregnancy.
    Adam MP; Polifka JE; Friedman JM
    Am J Med Genet C Semin Med Genet; 2011 Aug; 157C(3):175-82. PubMed ID: 21766440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teratogenesis and immunosuppressive treatment.
    Danesi R; Del Tacca M
    Transplant Proc; 2004 Apr; 36(3):705-7. PubMed ID: 15110638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drugs during pregnancy and breastfeeding: new risk categories--antibiotics as a model].
    Bertsche T; Haas M; Oberwittler H; Haefeli WE; Walter-Sack I
    Dtsch Med Wochenschr; 2006 May; 131(18):1016-22. PubMed ID: 16673226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Food and Drug Administration proposed testing guidelines for reproduction studies. Revision Committee. FDA Guidelines for Developmental Toxicity and Reproduction, Food and Drug Administration.
    Collins TF; Sprando RL; Shackelford ME; Hansen DK; Welsh JJ
    Regul Toxicol Pharmacol; 1999 Aug; 30(1):29-38. PubMed ID: 10464044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teratology Society 1998 Public Affairs Committee Symposium: the new thalidomide era: dealing with the risks.
    Friedman JM; Kimmel CA
    Teratology; 1999 Feb; 59(2):120-3. PubMed ID: 10069442
    [No Abstract]   [Full Text] [Related]  

  • 29. Sources of drug information: FDA-approved labeling and other official FDA sources.
    Lindstrom JA
    Dermatol Ther; 2009; 22(3):246-56. PubMed ID: 19453349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teratogen update: evaluation of the reproductive and developmental risks of caffeine.
    Christian MS; Brent RL
    Teratology; 2001 Jul; 64(1):51-78. PubMed ID: 11410911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dermatologic drugs, pregnancy, and lactation. A conservative guide.
    Reed BR
    Arch Dermatol; 1997 Jul; 133(7):894-8. PubMed ID: 9236528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statement of the Public Affairs Committee of the Teratology Society on the importance of smoking cessation during pregnancy.
    Adams J
    Birth Defects Res A Clin Mol Teratol; 2003 Nov; 67(11):895-9. PubMed ID: 14745924
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of prescription medications with a potential for fetal harm among pregnant women.
    Andrade SE; Raebel MA; Morse AN; Davis RL; Chan KA; Finkelstein JA; Fortman KK; McPhillips H; Roblin D; Smith DH; Yood MU; Platt R; H Gurwitz J
    Pharmacoepidemiol Drug Saf; 2006 Aug; 15(8):546-54. PubMed ID: 16586470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information Services.
    Schaefer C
    Congenit Anom (Kyoto); 2011 Mar; 51(1):6-11. PubMed ID: 21158950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population.
    Yang T; Walker MC; Krewski D; Yang Q; Nimrod C; Garner P; Fraser W; Olatunbosun O; Wen SW
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):270-7. PubMed ID: 18181228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Panel recommends limits on alcohol content of nonprescription products. FDA Over-The-Counter Drugs Advisory Committee.
    Am J Hosp Pharm; 1993 Mar; 50(3):400. PubMed ID: 8442445
    [No Abstract]   [Full Text] [Related]  

  • 37. Resolution of the Teratology Society. Teratogens and the Delaney Clause.
    Teratology; 1974 Oct; 10(2):1. PubMed ID: 4428418
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of a screening assay to identify teratogenic and embryotoxic chemicals using the zebrafish embryo.
    Selderslaghs IW; Van Rompay AR; De Coen W; Witters HE
    Reprod Toxicol; 2009 Nov; 28(3):308-20. PubMed ID: 19447169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isotretinoin prescribing: finding a balance between benefit and risk.
    Stern RS
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):611-3. PubMed ID: 16134100
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk management of marketed drugs: FDA and the interface with the practice of medicine.
    Uhl K; Honig P
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):205-8. PubMed ID: 11501332
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.